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Summary
A total of 40 skin fibroblast cultures from pediatric cases of lactic acidosis were subjected to a series of tests designed to elucidate the nature of an underlying defect in metabolism. Of these 40 cases, in 14 we were able to define the following problems.
Pyruvate carboxylase deficiency was evident in five cases showing <10% normal activity. Phosphoenolpyruvate carboxykinase deficiency was evident in one case where the whole cells showed 17% of normal activity whereas the mitochondria1 activity of this enzyme was 6% of normal. Pyruvate dehydrogenase deficiency was present in six cases showing 8 to 39% of normal activity, five of them being due to deficient pyruvate decarboxylase activity and one of them being due to deficient dihydrolipoyl dehydrogenase activity. Two cases were found with normal enzymes of pyruvate metabolism in which the production of '4COz from was deficient at 13 and 28% of normal activity, respectively, which we consider to be indicative of reduced activity of the Krebs' cycle. The grounds for the diagnosis of these 14 affected cases are documented, and the clinical presentation of these enzyme deficiencies is assessed in the light of present knowledge about lactic acidosis. Speculation years, the diagnosis being made most commonly on measurement of enzyme activity on a liver biopsy specimen. Where phosphoenolpyruvate carboxykinase (PEPCK) and pymvate carboxylase deficiencies are concerned, the number of cases are few, and the associated symptoms not always similar. Two diagnoses have been made based on the measurement of pyruvate carboxylase activity in fibroblasts (1, 10) ; in other cases, the diagnosis has been made on liver biopsy (29, 31, 33, 35) . Three cases of PEPCK deficiency have been documented, in two of which the localization of the defect is not specified (13, 15) . and in one of which the cytosolic PEPCK is identified as the missing component (36) .
Fatal lactic acidosis has been described in which postmortem examination of muscle tissue showed in one case deficient cytochrome aa3 and cytochrome b (34) , and in another case, deficient cytochrome aas (38) . In both cases, the defect seemed to be confined to skeletal muscle.
We present here the results of our studies on the skin fibroblasts from 40 new patients with lactic acidosis and attempt to correlate identifiable metabolic deficiencies with clinical presentation. 14 C-Labeled pyruvate, glucose, leucine, and valine were obWe that the continuing of the tained from Amersham Gorp., Ltd. (Oakville, Canada). [ I -' 4~] adiagnostic approach to pediatric cases of lacticacidosis as set out Ketoglutarate was obtained from New England Nuclear (Lachine, in this manuscript will eventually reveal the incidence, character, Quebec, Canada), and L~~1-~4clisoleucine was obtained from Galand clinical manifestations peculiar to the various enzyme defi-atomic (Los Angeles, L-aminoacid oxidase, catalase, and ciencies which collectively contribute to this syndrome. citrate synthase were obtained from Boehringer Mannheim, (St. Laurent, Quebec, Canada). Other biochemicals were from Sigma Hereditary enzyme deficiencies leading to lactic acidosis have Co. (St. MO). been demonstrated in two main areas: in the enzymes of the pyruvate dehydrogenase complex and in the key enzymes of the CULTURED FIBROBLASTS pathway of gluconeogenesis. The total PYruvate deh~drogenase Ex plants were grown from forearm skin biopsies taken with complex contains Six enzyme protein Components: the catalytic informed parental consent in Eagle's medium at 37°C with 15% sequence is composed of PYmvate decarboxylase (El) an fetal calf semm added. Confluent cells were harvested with 0.025% tetramer, dihydrolipoyl transacet~lase, and d i h~d r o l i~o~l dehy-trypsin. Cells used for studies were washed free of trypsin by drogenase (Ed. although there is a specific kinase and a ~h o s~h a -repeated ( X 3) centrifugation and resuspension of the packed cells tase modulating the activity of El (9. 26, 37) . At least nine in phosphate-buffered saline. confirmed cases of El deficiency have been described (3, 5, 6, 11, 12. 30) . A presumptive, but unproven, diagnosis of dihydrolipoyl WHOLE-CELL ASSAYS transacetylase deficiency has been made (8) , and two cases of Es deficiency have been described (14. 25) . We have previously Aliquots (150 to 600 pg cell protein) of trypsinized fibroblasts described a case of a specific pyruvate dehydrogenase phosphatase were added to I ml Kreb's phosphate buffer with the radiolabeled deficiency (24) . A specific kinase deficiency remains undescribed substrate contained in 25 ml Erlenmeyer flasks. The flasks were but presumably would not present with lacticacidosis.
MATERIALS AND METHODS

CHEMICALS
capped, and I4CO2 was collected on hyamine soaked (0.2 ml) filter Deficiencies of the gluconeogenic enzymes have been described paper inserts held in plastic wells attached to rubber stoppers. usually associated with both lactic acidosis and hypoglycemia. After the reaction period (90 min), the reaction was terminated by Deficiencies of glucose-6-phosphatase (16. 17) and fructose-1.6-the addition of 1 ml 0.08 M citric acid, and a further 35-min diphosphatase (20. 21) have been recognized for a number of collection period followed. The filter inserts were removed with 956 forceps and placed in 10 ml toluene ethanol (9:l v/v) scintillation BRANCHED-CHAIN KETO ACID DEHYDROGENASE fluid with 0.5% 2,s-diphenyloxazole, and 0.03% 1,4-bis [2-(5-phenyloxazoylyl) ]benzene added. The I4C activity was counted via Beckman LS-355 liquid scintillation spectrometer. Appropriate control incubations were conducted for such experiment to account for nonenzymatic I4CO2 production, and all incubations were performed in duplicate. Pyruvate oxidation rates were determined using a concentration of 0.5 mM pyruvate with 0.35 pCi of [I-14C]pyruvate or [3-14C] 
PYRUVATE DEHYDROGENASE-TOTAL COMPLEX
This was carried out by a modification of the method of Taylor et al. (33) . Trypsinized washed cells (I mg protein) were suspended in 0.8 ml of a buffer containing 10 mM phosphate, 1 mM EDTA, 1 mM dithiothreitol, and 1% fatty acid-free bovine serum albumin (pH 7.4). The cells were then disrupted by sonication (2 x 10 sec on 30% power output of Artek Ultrasonic Dismembrator). Fifty g cell protein were added to 0.2 ml of a buffer of the same composition as above, but containing in addition 2 mM MgC12, 0.15 mM CoASH, 1.6 mM NAD, 0. l mM TPP, 0.25 mM pyruvate, and 0.25 pCi/ml [I-14C]pyruvate. The reaction volume was contained in a small plastic tube lodged in 25 ml Erlenmeyer flasks, and the flasks were carefully sealed by rubber stoppers filled with plastic well containing 0.2 ml hyamine hydroxide. After 45 min incubation at 37OC. the hyamine was removed by syringe from each plastic well, the well was washed with 0.4 ml ethanol, and they hyamine and ethanol were added to 10 ml to1uene:ethanol (9:l) scintillation mixture described above. For total pyruvate dehydrogenase, Mg"' (10 mM) and Ca"+ (10 mM) were added to ensure that the enzyme was fully activated. Controls with no cell protein or acid denatured cell protein were run simultaneously to account for nonenzymatic I4C02 production. Inclusion of an acidification step gave no further increase in the yields of I4CO2 using this method.
PYRUVATE DEHYDROGENASE El
This was measured by slight modification of the technique described by Blass et al. (3) . Assay volumes were reduced from 1.0 to 0.2 ml, 100 pm cell protein was added to each incubation for decarboxylase determination, and I4CO2 was collected in hyamine rather than sodium hydroxide.
PYRUVATE DEHYDROGENASE Ei
This was measured by two methods. In the direction lipoamide to reduced lipoamide, the modified method of Reed and Wilms (22) was used. Sonicated trypsinized and washed fibroblasts (50 to 300 pg cell protein) were added to identical cuvettes containing I ml 0.15 M phosphate buffer (pH 8.1) 0.2 mM NADH at 37°C. The decrease in absorbance from a steady state was measured at 340 nM in a split-beam spectrophotometer (Pye Unicam SP 1800) on addition of 2.5 mM lipoamide to the test cuvette. In the opposite direction, the method of Melancon et al. ( 19) was used at pH 7.8.
2-OXOGLUTARATE DEHYDROGENASE
This was measured exactly as for pyruvate dehydrogenase total active complex except that 2-oxoglutarate and 2-[l-'4C]oxoglutarate were used instead of pyruvate and [I-14C]pyruvate.
2-OXOGLUTARATE DECARBOXYLASE
This was measured exactly as for pyruvate decarboxylase except that 2-oxoglutarate and 2-[1-'4C]oxoglutarate were used instead of pyruvate and [l-14C]pyruvate. This was measured as for pyruvate dehydrogenase except that I-I4C-labeled a-ketoisovalerate was used as substrate instead of [~-~~C ]~~r u v a t e .
I-I4C-Labeled branched chain keto-acids were prepared from the corresponding branched chain amino acids by the method of Rudiger et al. (28) .
PYRUVATE CARBOXYLASE
Pyruvate carboxylase was measured by the method of Atkin et al. (1) modified such that the specific activity of NaHI4CO:, was 10 times higher at 1 mCi/mmole, and the cells were disrupted by sonication rather than freeze-thawing. This latter modification was found to be a faster method than freeze-thawing because there was no difference in enzyme activity measured after either treatment.
PEPCK
This was assayed by two methods. In the direction of phosphoenolpyruvate formation, the method of Roobol and Alleyne (27) was used with a minor modification in that the rate of reduction of NAD was monitored fluorimetrically to give greater sensitivity and that 0.05% Triton X-100 was included in the incubation medium to disrupt the added mitochondria or fibroblasts. In the direction of oxoloacetate formation, the method of Ballard and Hanson (2) was used again in the presence of Triton X-I00 (0.05%) to disrupt either mitochondria or fibroblasts. All of the above assays were carefully monitored in time courses, and the times selected for the running of each assay were in the linear portion of the progress curve for the reaction.
PATIENT MATERIAL
Fibroblasts were accepted for study if the patient's presentation met with certain criteria. ( I ) The patient must have a demonstrable lacticacidemia on a chronic or episodic basis with blood lactate values >2 mM. (2) There must be no evidence of primary cardiorespiratory or liver disease or metabolic alkalosis. Clinical tests should have ruled out glucose-6-phosphatase and fructose-1,6-diphosphatase deficiency. (3) Analysis of urine organic acids should reveal no abnormal accumulation of organic acids other than lactate:pyruvate,3-hydroxybutyrate, and acetoacetate.
INVESTIGATION OF PYRUVATE METABOLISM IN FIBROBLASTS
There are, as we described in the introduction, a number of possible areas in which an enzyme deficiency could lead to lactic acidosis. These areas can be roughly divided into the pathway of gluconeogenesis, the behavior of the pyruvate dehydrogenase complex, and the operation of the Krebs' cycle and cytochrome system (Fig. I) .
Reactions involved in the production and utilization of pyruvic and lactic acids. Key enzymes denoted are pyruvate dehydrogenase (PDH), pyruvate carboxylase (PC), and PEPCK.
Because we asked that glucose-6-phosphatase and fructose-1,6-phosphatase deficiency be ruled out clinically before we started fibroblast investigations, this meant that in the area of gluwneogenesis we were looking at the activities of pyruvate carboxylase and PEPCK. It has been reported that the PEPCK in fibroblasts is almost exclusively mitochondria1 (1), so this means in effect that out tests would not exclude cytosolic PEPCK deficiency. Thus only part of the gluwneogenic pathway is present in fibroblasts.
All cell lines were assayed for pyruvate carboxylase and PEPCK activities.
FLW CHART FOR TESTING CELLS
---
To assess flow through pyruvate dehydrogenase, whole-cell [I-14C]pyruvate oxication to '"COZ was measured. Two measurements of pyruvate dehydrogenase activity were made, one of the native activity present in fibroblasts on sonication and another after full activation in the presence of CaZ'. In the event of low pyruvate dehydrogenase activity being found, two of the subcomponents of the complex, El and E3, were measured. If E g was deficient, measurement was also made of branched-chain keto acid dehydrogenase and both the 2-oxoglutarate dehydrogenase and decarboxy lase.
Flow from glucose down through glycolysis through pyruvate dehydrogenase and into the Krebs' c cle was assessed by following the oxidation of [U-'4C]glucose to k02. Krebs' cycle flux was assessed by measuring the activity of the cells in oxidising 13-"C] pyruvate to '"COz because two turns of the cycle are required before any label from this moiety is evolved as COz. A flow chart for these activities is shown below (Fig. 2) . in which this enzyme was deficient. In all cell lines, the residual Fig. 2 . Flow chart to show sequence of investigations in cultured skin activity measured was less than IWo of the control values obtained fibroblasts used in this study. PC, pyruvate carboxylase; aKgDH, a- (Table 1 ). In the same table, we also document the pyruvate ketoglutarate dehydrogenase; BCKADH, branched-chain keto acid dehy-dehydrogenase activity of these cell lines which were all in the drogenase. normal range. Measurement of the activity of PEPCK revealed only one cell line which was deficient, where the activity was 17% of the controls (Table 2 ). In isolated mitochondria from this patient's fibroblasts, we have shown the activity of PEPCK to be 6% of normal (23) . Normal values of pyruvate carboxylase and dehydrogenase activity were found with this cell line.
PYRUVATE DEHYDROGENASE
Six cell lines with pyruvate dehydrogenase deficiency were evident in our studies. The amount of activity measurable in pyruvate dehydrogenase varied from 8 to 39% of the controls in these deficient cell lines (Table l) , and pyruvate carboxylase was normal or greater than normal in all cases.
Further investigation of these cell lines revealed five of them to be deficient in the first subenzyme of the complex, El, and one of them to be deficient in E3 with less than normal El activity (Table  3 ). This latter cell line also had deficient 2-oxoglutarate dehydrogenase (39% of normal) and branched-chain keto-acid ( 4 % of 
WHOLE-CELL PYRUVATE OXIDATION
(1-"C]Pyruvate oxidation in whole cells was significantly lower for all cell lines with pyruvate dehydrogenase deficiency (El) than in control cell lines (average, 37% of controls). However, in the case of pyruvate dehydrogenase (E3) deficiency the rate, although statistically significantly lower, was 75% of controls. Cell lines with Tyruvate carboxylase deficiency did not show reduced rates of [l-Clpyruvate oxidation (Table 4) .
13-"CIPyruvate oxidation was noticeably deficient in all cell lines with pyruvate dehydrogenase deficiency. It was also found to be deficient in two cell lines where [I-'4C]pyruvate oxidation, and all other enzyme measurements were normal ( Table 4) . Both of these cell lines were the only lines in which [U-14C]glucose + I4COz was found to be deficient. Cell lines with pyruvate dehydrogenase deficiencies showed no marked difference in glucose oxidation rates (Table 5 ).
SUMMARY OF RESULTS
The investigation of a total of 40 patients with lactic acidosis yielded five cases of pyruvate carboxylase deficiency, one case of mitochondria1 PEPCK deficiency, and two cases with defective [3-'4C] (3) 6.97 * 0.61 (2) 8.94 * 0.51 (2) 81 1 1.92 f 0.61 (5) 4.19 f 1.03 (5) 7.57 f 0.803 (3) 7.80 * 1.18 (3) 936 0.887 f 0.043 (3) 6.06 f 1.77 (3) 6.9 (1) 11.6 (1) 584 1.290 * 0.385 (3) 3.52 * 0.45 (3) 0.303 * 0.012 (3) 9.7 f 0.41 (3) El and EJ activities in cell lines with pyruvate dehydrogenase deficiency were determined as described in "Materials and Methods."
Numbers in parentheses, number of determinations. (4) 3.3 1 rt 0.655 (4) 5.424 * 1.240 (5) 4.23 f 1.05 (3) 6.041 f 1.89 (3) 3.35
Assays of whole-cell pyruvate oxidation were carried out as described in "Materials and Methods." PDH, pyruvate dehydrogenase.
' Numbers in parentheses, number of determinations.
atomegaly, delayed neurological development, and failure to thrive. The actual presentation of any one child may involve just one or several of these presenting signs, and these are summarized for each of the patients in which we have found a deficiency (Table 6 ). There is obvious variability in the patients diagnosed as having pyruvate dehydrogenase-El deficiency; there is some similarity between patients 825 and 828 (who are sibs) and patient 81 1, in that all showed failure to thrive and delayed neurologic development. Patient 911 presented at 18 months with ataxic episodes and seizures, whereas patient 936 died at the age of 16 days with overwhelming acidosis. Most of the cases reported by Blass et al. (4) with pyruvate decarboxylase deficiency were late onset (2 to 5 years) cases with intermittent ataxia as a major presenting problem. Patient 91 1 falls into this category. The early type of presentation of El deficiency with severe acidosis starting .' Numbers in parentheses, number of determinations.
in the neonatal period is reported by Blass et al. (4) for one case, and similar cases were reported by Stromme et al. (30) and Farrel el al. (12) . All have been fatal as was the case in patient 936 and will probably be the outcome in patient 81 1. The reasons for the difference between these two types of presentations are not exactly clear. The overall activities in patients 936 and 81 1 of pyruvate dehydrogenase are somewhat higher than for the other El deficiencies which does not explain the more acute presentation. None of these pyruvate dehydrogenase-El deficiency cases have a defect in 2-oxoglutarate dehydrogenase (results not shown). Thus, the fact that the El enzyme is an a n & subunit tetramer (26) makes it possible that the two types of El presentation represent a defect in different subunits but there is no experimental evidence to support such an hypothesis at this time.
We have previously reported a case of a male child who died at 7 months with pyruvate dehydrogenase-Es deficiency (25) where the diagnosis was made on postmortem tissue enzyme activity. The case which we have diagnosed here represents the second case we have diagnosed, but this time, the enzyme assays were performed on skin fibroblasts. This patient, like our first, had elevated levels of branched-chain amino acids in the plasma and a deficient 2-oxoglutarate and branched-chain keto acid dehydrogenase activity. The presentation of this case with chronic acidosis, delayed neurological development, failure to thrive, and hypoglycemia was very similar to that reported for the previous patient (25) .
From the cases in the literature, this deficiency has a somewhat heterogenous phenotype. There appears to be one form of the disease which presents early in life with chronic lacticacidemia, neurologic problems, and fasting hypoglycemia (I, 10, 29, 35) and another which presents between one year and 5 years as degenerative neurological disease resembling Leigh's encephalopathy (18, 31, 32) . The cases we report here fall into the first category having early onset, chronic acidosis, and either seizures or delayed neurologic development. Fasting hypoglycemia is not always ap- parent. It is interesting that in the two previously documented cases in which fibroblast studies have been performed to obtain the diagnosis, the presentation has been that of the early onset group (1, 10). The low levels of enzyme activity reported here by ourselves and by others in the early onset form of this disease (1, 10, 29, 35) are lower than those reported for the later presentation (29, 31, 32) . All of the patients reported here are of North American Indian heritage.
PEPCK
The presentation of our patient with PEPCK deficiency will be discussed in greater detail in a forthcoming publication (23) , but for the purposes of this survey, it is interesting to note the symptoms of hypoglycemia with muscular hypotonia were similar to those reported by Hommes el al. (15) . In the case reported by Vidnes and Sovik (36) , there was hyperplasia of the endocrine pancreas associated with hypoglycemia and hepatomegaly, and there was the possibility of the observed deficiency of cytosolic PEPCK in the liver being secondary to hyperinsulinism.
DEFICIENT Oxidation of [3-14C] pyruvate to I4CO2 involves the passage of the third carbon of pyruvate through two complete turns of the Krebs' cycle before the I4C02 is released. It is not surprising that cell lines from patients with pyruvate dehydrogenase deficiency therefore have a low rate of [3-14C] pyruvate oxidation. However, we have demonstrated two cell lines in which there is a deficiency of [3-'4C] pyruvate oxidation where there is normal pyrdvate dehydrogenase activity and [l-14C]pyruvate oxidation. We can only conclude from these observations that these two patients have altered citric acid cycle flux such that either there is a partial blockage of the citric acid cycle or there is significant dilution of the labeled pool of metabolites at some point in the cycle that is only evident in these cells. To our knowledge, no such defect has been previously documented.
The presentation of these patients is rather different in that in one (patient 790) acidosis is a major problem, the lactic acid level is high, and there is ataxia and delayed neurologic development on a chronic basis. In the other case, the lactate is not chronically elevated, and the patient suffers episodic bouts of seizures and ataxia.
The other surprising finding In the cells tiom these two patlents was that the rate of [U-14C]glucose metabolism to I4CO2 was slower than in controls (Table 6 ). This parameter in trypsinized skin fibroblasts remains unchanged in patient 81 1 with pyruvate dehydrogenase-El deficiency or in patient 584 with pyruvate dehydrogenase Ea deficiency. The interpretation of this finding is difficult because, although the rate of pyruvate oxidation is almost the same in trypsinized and nontrypsinized cells, the rate of glucose oxidation is much lower in trypsinized cells (unpublished observation). Borud and Stromme (7) showed that a cell line defective in pyruvate dehydrogenase-El activity oxidized [L'-I4C] glucose to I4CO2 at a rate of 60% that of control cells. We have found that the inability of the two cell lines to oxidize g l u c o s e t o '4COp a t a p p r o p r i a t e r a t e s f u r t h e r reflects t h e d i s t u r bance that must be affecting Krebs' cycle flux. Inability to properly oxidize pyruvate fully to CO:! and water in the tissues of these patients must lead in some way to a decreased overall turnover of pyruvate. Why this is not reflected in [I-14C]pyruvate oxidation is a matter for further investigation and should increase our knowledge not only of Krebs' cycle control mechanisms but also of the problem in these two patients.
CONCLUSIONS
From a total of 40 patients with lactic acidosis, we have been able to identify the precise location of the enzymic deficit in 12 and tentatively identify the area in which the deficit is located in an additional two of these patients. This leaves a rather large number of patients, 28, in which we cannot find the underlying deficiency. Our failure to do so may stem from three basic reasons: (I) the enzyme deficiency may not be well expressed in fibroblasts, e . g , cytosolic PEPCK; (2) the deficiency may be expressed in fibroblasts, but our tests are not sensitive enough to measure it, e.g., pyruvate dehydrogenase phosphatase; (3) the lactic acidosis may be a secondary phenomenon resulting from a primary block elsewhere in metabolism, e.g., fatty acid or branched-chain amino acid oxidation. We are actively searching for new ways to probe cell lines for which we can demonstrate no defect and are confident that our screening system can be made more comprehensive with the addition of further tests. Only when the root cause of lactic acidosis in all of the patients studied has been found can we hope to devise a comprehensive approach to this problem.
